Latest News

  • Cambridge Cognition and Altreos Research Partners, Inc. join forces as FDA guidelines drive demand for Human Abuse Liability studies
    The release of two key draft FDA Guidances on abuse liability assessments on drugs* and abuse-deterrent products has resulted in increased demand for human abuse liability studies. In response, Cambridge Cognition, the global leader in touchscreen cognitive assessments for clinical trials, has formed a scientific partnership with Altreos Research Partners, Inc., a leading provider of scientific, regulatory and operational input on abuse liability assessments.
  • Could data sonification deliver while-you-wait cancer diagnosis?
    Converting stem cell data into sounds could enable GPs to make instant, non-invasive cancer diagnoses during a routine check-up.With waiting times for cancer tests at a six-year high, this could significantly reduce the agonising and potentially life-threatening wait for patients and improve Government waiting time targets.*
  • Twin hearing study helps discover gene that influences hearing ability
    The largest ever genome wide association study on hearing ability has identified the salt-inducible kinase 3 (SIK3) gene as a key influencer in how well we can hear, particularly at high frequencies. This significant new finding by King's College London, co-funded by charities Action on Hearing Loss and Age UK, increases the understanding of the causes of hearing loss, which affects 10 million people in the UK and could lead to future treatments.
  • Self-assembling anti-cancer molecules created in minutes
    Like a self-assembling ‘Lego Death Star’, says lead researcher
  • A Gene Linked to Disease Found to Play a Critical Role in Normal Memory Development
    It has been more than 20 years since scientists discovered that mutations in the gene huntingtin cause the devastating progressive neurological condition Huntington’s disease, which involves involuntary movements, emotional disturbance and cognitive impairment. Surprisingly little, however, has been known about the gene’s role in normal brain activity.
view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

view more

25 Hottest Articles

view more